We use cookies to improve our services. Read more about how we use cookies and how you can refuse them.
2019
EMCDDA
EMCDDA Harm Reduction Initiative
Supporting the HCV elimination agenda - an EMCDDA initiative to increase access to hepatitis C care in drug services
2019
Clinical Gastroenterology and Hepatology
Coffee and Caffeine Are Associated With Decreased Risk ofAdvanced Hepatic Fibrosis Among Patients With Hepatitis C
Coffee or caffeine has been proposed to protect against hepaticfibrosis, but few data areavailable on their effects in patients with chronic hepatitis C virus (HCV) infection
2019
Hindawi Publishing Corporation
Linoleic Acid Induced Acute Hepatitis: A Case Report and Review of the Literature
Several dietary supplements used for weight loss have been reported to cause hepatotoxicity. Conjugated Linoleic Acid (CLA) is adietary supplement that has been shown to cause reduction in body fat mass. Here, we present the first case of CLA induced acutehepatitis in the United States and only the third case in the worldwide literature along with a brief review of the literature.
2019
Endocrinology 2015
Fish Oil Rich Diet Promotes Hematopoiesis and AltersHematopoietic Niche
Study shows that a diet rich in fish oils promotes self-renewal of hematopoietic stem cells and extramedullary hematopoiesis
2019
HCV Advocate Magazine, 2015
A Brief Overview of Liver Toxic Herbs
This review will focus on the important issues regarding the lack of standardization, possible contamination, some deceptive claims and a list of the herbs that have the most potential to harm the liver.
2019
Gastroenterology 2015
Association Between Psychological Distress and Liver DiseaseMortality: A Meta-analysis of Individual Study Participants
Based on a meta-analysis, psychological distress is associated with liver disease mortality, although this finding requires additional analysis.
2019
Gastroenterology 2015
On Stress and the Liver: A Chicken and Egg Conundrum
A theme common to contemporary pathophysiology is that we are constantly being bombarded by stressors that have deleterious effects on organ structure and function.
2019
Hepatitis Central
Tired with Hep C? Avoid These5 Foods!
Individuals with Hepatitis C can impact the course of their illness with their daily food choices. Fatigue adds another layer of culpability to the foods we choose to eat. Besides potentially aiding or impairing liver detoxification, certain foods can also drain energy levels.
2019
Hepatitis Central
Top 10 Sources of ProteinIntake for Hepatitis C
Find out why most people with Hepatitis C need to eat plenty of protein, and which protein sources are the best.
2019
Chinese medicine
Traditional Chinese Medicine and HCV
Article provides a through overview of Chinese medicine and herbal treatments for HCV
2019
Journal of Hepatology
Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review.
Complementary therapies are widely promoted for and used by patients with hepatitis C. The aim of this article was to systematically assess the efficacy of complementary therapies in treating chronic hepatitis C.
2019
Hepatology
How Does Coffee Prevent Liver Fibrosis? Biological Plausibility for Recent Epidemiological Observations
The published epidemiological data demonstrates an inverse relationship between coffee (and potentially other caffeinated beverage) consumption and liver fibrosis and its downstream complications are weighty and rapidly accumulating. Several excellent recent reviews examine this evidence in great detail, and the overwhelming conclusion is that this inverse relationship is real—coffee drinking reduces liver fibrosis.
2019
Alternative Medicine Review, Volume 4, Number 4
Hepatitis C - Epidemiology and Review of Complementary/Alternative Medicine Treatments
The hepatic damage is due both to the cytopathic effect of the virus and the inflammatory changes secondary to immune activation. The use of the botanical components glycyrrhizin, catechin, silymarin and phytosterols, and the antioxidants N-acetylcysteine and vitamin E are reviewed for their efficacy in treating chronic hepatitis and affecting liver damage.
2019
Get The Facts
Hepatitis C Focus on Dietary Supplements
Conventional medical treatments are available for chronic hepatitis C. Some people with hepatitis C also try complementary health approaches, especially dietary supplements. This fact sheet provides basic information on hepatitis C, summarizes scientific research on selected supplements, and suggests sources for additional information.
2019
CID 2013
Marijuana does not Accelerate Liver Disease in HIV–HCV Coinfection
Marijuana smoking is common and believed to relieve many symptoms, but daily use has been associated with liver fibrosis in cross-sectional studies. We aimed to estimate the effect of marijuana smoking on liver disease progression in a Canadian prospective multicenter cohort of HIV/HCV co-infected persons.
2019
Gastroenterology 2014
Increased Intake of Vegetables, but not Fruit, Reduces Risk for HepatocellularCarcinoma: A Meta-analysis
Based on a meta-analysis, increased intake of vegetables, but not fruit, is associated with lower risk for HCC. The risk of HCC decreases by 8% for every 100g/day increase in vegetable intake. The findings should be confirmed by future studies with validated questionnaires and strict control of confounders.
2019
Hepatitis Central
The Top Three Alternative Treatments for Hepatitis C
For those who are not able to conquer the Hepatitis C virus with combination therapy, discover three holistic approaches that can help improve your treatment odds and/or stave off liver damage.
2019
Addiction
Decline in incidence of HIV and hepatitis C virusinfection among injecting drug users in Amsterdam;evidence for harm reduction?
In Amsterdam, HIV prevalence has nearly halved among injecting drug users (IDU) since 1990. Hepatitis C virus (HCV) prevalence also declined; HIV and HCV incidence dropped to nearly zero. We examined possible explanations for these time trends, among which the implementation of harm reduction measures aimed at reducing the risk behaviour of IDU.
2019
The Lancet
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
Up-to-date evidence about levels and trends in disease and injury incidence, prevalence, and years lived with disability (YLDs) is an essential input into global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013), we estimated these quantities for acute and chronic diseases and injuries for 188 countries between 1990 and 2013.
2019
Journal of Viral Hepatitis, 2015
Estimates on HCV Disease Burden Worldwide - filling the gaps
As resources are limited, solid data to estimate the disease burden caused by HCV are urgently needed. Epidemiology data and disease burden analyses for 16 countries are presented.
2019
The bleach procedure
Instructions on how to use bleach procedure for disinfection for penal institutions
2019
The Lancet. August 16, 2018
Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis
There are concerns around poorer response to direct-acting antiviral (DAA) therapy for hepatitis C virus infection among people who use drugs. This systematic review assessed DAA treatment outcomes among people with recent drug use and those receiving opioid substitution therapy.
2019
Health Promotion Practice, Lauren Knight et al.
Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs
Peer-supported and strongly integrated, comprehensive HCV care will help PWID reach high uptake and adherence to c
2019
International Journal of Drug Policy 52 (2018) 16–19
Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia. Tamar Kikvidze et al.
Peer support can enable patient engagement with healthcare services, particularly for marginalised populations. In this randomised controlled trial, the efficacy of a peer support intervention at promoting successful engagement with clinical services for chronic hepatitis C was assessed.
2019
J Hepatol (2017)
Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. Carriere MP et al.
Coffee has anti-inflammatory and hepatoprotective properties. In the general population, drinking ≥3 cups of coffee/day has been associated with a 14% reduction in the risk of all-cause mortality. The aim of this study was to investigate the relationship between coffee consumption and the risk of allcause mortality in patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Methods: ANRS CO13 HEPAVIH is an ongoing Fre
2019
BMC Medicine (2019) 17:71
Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention, R. Stagg et. al.
Peer support can enable patient engagement with healthcare services, particularly for marginalised populations. In this randomised controlled trial, the efficacy of a peer support intervention at promoting successful engagement with clinical services for chronic hepatitis C was assessed.
2019
The Lancet October 23, 2017
Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Larney, et. Al
Coverage of HIV and HCV prevention interventions for PWID remains poor and is likely to be insufficient to effectively prevent HIV and HCV transmission. Scaling up of interventions for PWID remains a crucial priority for halting the HIV and HCV epidemics.
2019
Infect Dis Clin N Am 32 (2018) 395–405
Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men, Martin et al
Behavioral interventions studies addressing hepatitis C virus reinfection are required, such as the ongoing HCVree trial in Switzerland. Other interventions may include traditional harm reduction interventions, adapted behavioral interventions, and interventions to prevent risk related to substance use with sex.
2019
Treatment Action Group
Training Manual for Treatment Advocates; Hepatitis C Virus & coinfection with HIV, Annette Gaudino, Bryn Gay, and Tim Horn
A primary goal of the Training Manual is to increase advocates’ knowledge about available HCV tests and treatments and to jumpstart discussions on advocacy strategies that can be used to open up affordable access for more people with HCV.
2019
Correlation, INPUD, Swedish Drug User Union
Liver or Die: HCV Training for Peer Workers
HCV capacity building training for harm reduction programs and peer workers
2019
Correlation
Hepatitis B and C testing: Why? Who? How?
This paper aims to stimulate services to engage in HCV and HBV awareness raising and in particular to inform community members, social and health care practitioners about current HBV/HCV testing and diagnosis methods, screening technologies and other aspects around the issue.
2019
Correlation
Hepatitis C Testing in the Community
This booklet provides a comprehensive overview of HCV testing in the community, looking at benefits, effective models, public health burden, policy and barriers.
2019
Correlation
Online Peer Support Manual
This website provides access to comprehensive resources for organisations and peer workers. Here you can find information on how to support peer workers from organisations and the peer workers.
2019
E. Gupta et al. Journal of Clinical Virology 88 (2017) 46–51
Point -of -care testing (POCT) in molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection
Molecular testing atthe point-of-care may turn outto be game changer for HCVdiagnosis and treatment monitoring, through increased sensitivity, reduced turnaround time, and ease of performance. One such assay GeneXpert® has recently been released. Comparative analysis between performances of GeneXpert® and Abbott HCV-RNA was done
2019
Infect Dis Clin N Am 32 (2018) 371–393
Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. Martinello et al
One challenge to achieving HCV elimination through therapeutic intervention is reinfection. There is concern that HCV reinfection may compromise HCV treatment outcomes in populations with ongoing risk behaviors, with the risk of reinfection cited as a reason for not offering treatment to PWID. This review summarizes the literature regarding reinfection after successful HCV treatment among PWID, discusses strategies to reduce HCV infection and reinfection, and highlights the potential individual- and population-level impact of DAA treatmentscale up on HCV elimination.
2019
Journal of Hepatology 2018
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. Fraser H et al.
2019
The Journal of Infectious Diseases 2018;217:466–73
Recovery of Infectious Hepatitis C Virus From Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs. Heimer et al.
Hepatitis C virus could not be recovered from cookers regardless of input syringe type or cooker design. Recovery was higher when comparing detachable needles to fxed needles for residue in input syringes (73.8% vs 0%), flters (15.4% vs 1.4%), and receptive syringes (93.8% vs 45.7%).
2019
Journal of Hepatology 2017
M. Hellard et al. Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond
The implication of this work is that for many countries the elimination of hepatitis C as a public health threat is not going to happen by chance. A number of barriers need to be overcome, requiring a focused effort from governments and health services. The first barrier is that widespread treatment scale-up is currently precluded by restricted and inconsistent access policies in many European countries.3,4
2019
Jeffrey V. Lazarus et al. Journal of Hepatology 2017
Micro-elimination – A path to global elimination of hepatitis C
The micro-elimination approach encourages policymakers and other stakeholders to set pragmatic national and subnational goals, while the people who are best informed about the nature of the HCV epidemic in their sub-population can take the lead in tailoring interventions to address its specific circumstances.
2019
J.Farrell, E.Schatz 2019 Correlation European Harm Reduction Network
Legal Barriers for Providing HCV Community Testing in Europe
Correlation European Harm Reduction Network conducted a telephone survey with representatives of harm reduction services and of NGOs that offer low-threshold services to drug users. During the months of September and October 2018, a total of twenty (20) organizations in 18 countries, participated in this survey and provided information on the state of affairs with regards to community testing in their country
2019
Correlation European Harm Reduction Network
HCV in Integrated Harm Reduction Services
Drug users journey to access health care
2019
Correlation European Harm Reduction Network
Hepatitis C Community Summit 2018
Presentations and highlights from the summit
2019
Correlation European Harm Reduction Network
HCV Community Testing
Overview of HCV community testing
2019
Carmen Rossi et al, Journal of Hepotology Nov 2018
Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort
Direct-acting antiviral therapies (DAA) are an important tool for hepatitis C virus (HCV) elimination. However, reinfection among people who inject drugs (PWID) may hamper elimination targets. Therefore, we estimated HCV reinfection rates among DAA-treated individuals, including PWID.
2019
International Journal of Drug Policy 62 (2018) 104–111
Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study
People who inject drugs (PWID) are often excluded from HCV treatment programs due to concerns about their ability to adhere to care. Georgia has a high prevalence of HCV infection (5.4% of chronic cases in general population) with an epidemic concentrated among PWID. We evaluated adherence to care and sustained virologic response (SVR) among PWID in Georgia.
2019
The Lancet. Published Online January 28, 2019
Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Alastair Heffernan et al.
We evaluated the impact of public health interventions on the global HCV epidemic and investigated whether WHO’s elimination targets could be met.
2019
Journal of Hepatology 2017
Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond. M. Hellard et al.
The implication of this work is that for many countries the elimination of hepatitis C as a public health threat is not going to happen by chance. A number of barriers need to be overcome, requiring a focused effort from governments and health services. The first barrier is that widespread treatment scale-up is currently precluded by restricted and inconsistent access policies in many European countries.3,4
2019
Lancet Gastroenterol Hepatol 2018
Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis
The research team compiled deidentified questions during field enrollments. Results. FAQs were reviewed and categorized into four major domains, including risk/prevention, screening, treatment, and reinfection. FAQs were addressed by a team of medical and public health professionals, using the most current research and recommendations.
2019
2017 European Association for the Study of the Liver.
Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients, Maria P. Carrieri, et al.
Coffee has anti-inflammatory and hepatoprotective properties but its effect on mortality risk has never been investigated in patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). This study shows that elevated coffee consumption (≥3 cups/day) halves all-cause mortality risk in patients co-infected with HIV-HCV. The benefits of coffee extracts and supplementing dietary intake with other anti-inflammatory compounds need to be evaluated in this population.
2019
Infect Dis Clin N Am 32 (2018) 425–445
Hepatitis C Virus Diagnosis and the Holy Grail
It is not often the world has the opportunity to turn a public health crisis into a good news story. The development of oral, highly effective, pangenotypic direct-acting antivirals (DAAs) has now paved the way to cure the 71 million people estimated to be living with chronic hepatitis C virus (HCV) infection globally. This report highlights improving access to rapid, simple, and affordable HCV diagnostics is critical to achieve global HCV elimination.
2019
www.thelancet.com
EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities
The increasing health burden, the advent of novel and costly therapies, and the changing epidemiology demand innovative approaches and solutions for patients with liver diseases in European countries, which also face major demographic changes. By working with governmental and non-governmental organisations, such strategies must overcome cultural, ethical, and lifestyle barriers to vaccines and other preventive measures for obesity and alcohol consumption. F
2019
Hepatology, January 2019
Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period? Jain et, al
Direct-acting antivirals (DAA) for hepatitis C virus (HCV) became available in 2014, but the role of mental health or substance use disorders (MH/SUD) on access to treatment is unknown. The objective of this study was to examine the extent and predictors of HCV treatment in the pre-DAA and post-DAA periods in four large, diverse health care settings in the United States.
2019
WHO Regional Office for Europe
Action plan for the health sector response to viral hepatitis in the WHO European Region
This very first Action plan for the health sector response to viral hepatitis in the WHO European Region has been developed through a truly inclusive consultative approach. It draws on the expertise of an advisory committee and has benefited from the input of Member States, major partners and civil society, including patient organizations which represent the people who live with viral hepatitis in Europe.
2019
The Lancet: VOLUME 5, ISSUE 12, PE1208-E1220, DECEMBER 01, 2017
Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review
A country-level, regional, and global estimates of coverage of NSP,
OST, HIV testing, ART, and condom programmes for PWID
OST, HIV testing, ART, and condom programmes for PWID
2019
Journal of Hepatology 2018 Mar
Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond
The implication of this work is that for many countries the elimination of hepatitis C as a public health threat is not going to happen by chance. A number of barriers need to be overcome, requiring a focused effort from governments and health services
2019
WHO Regional Office for Europe
Action plan for the health sector response to viral hepatitis in the WHO European Region
This first Action plan for viral hepatitis in the WHO European Region adapts the Global health sector strategy on viral hepatitis, 2016–2021 to the context of the European Region. The plan was developed through a participatory process, finalized and endorsed at the 66th session of the WHO Regional Committee for Europe, along its resolution EUR/RC66/R10.
2019
Am J Public Health.
Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. Zibbell et al.
These findings strongly suggest that the national increase in acute HCV infection is related to the country's opioid epidemic and associated increases in IDU.
2019
J. Walker et al. bioRxiv preprint first posted online Feb. 24, 2018
Interim impact evaluation of the hepatitis C virus elimination program in Georgia
The Georgia HCV elimination program has accomplished an impressive scale up of treatment, which has already impacted on prevalence and incidence, and averted deaths due to HCV. However, extensive scale up is needed to achieve a 90% reduction in prevalence by 2020.
2019
World Health Organization; 2019
Progress report on HIV, viral hepatitis and sexually transmitted infections, 2019 Accountability for the global health sector strategies, 2016–2021
WHO is accountable for reporting back to the World Health Assembly on progress in implementing the strategies based on data received from countries. This report assesses the mid-term progress in 2019 in implementing these global health sector strategies from 2016 to 2021.
2019
EMCDDA 2019
Hepatitis C: New Models of Care for Drug Services
This collection of case studies was commissioned by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA contract CT.17.HEA.0088.1.0) to promote the dissemination of good implementation practices in the field of hepatitis C testing and care for people who inject drugs.
2019
WHO
WHO Hepatitis C Fact Sheet
WHO fact sheet provides the most recent information about HCV prevention, treatment and testing
2019
TAG 2019
Treatment Action Group: Pipeline Report HCV Diagnostics
This report provides an overview of HCV diagnostic screening products and point of care testing developments worldwide.
2019
TAG 2019
Treatment Action Group: Pipeline Report HCV Treatments
This report provides an overview of HCV treatment developments worldwide. With information about when new medications will be available.
2019
TAG 2019
Treatment Action Group: Hepatitis Fact Sheets
TAG prepared a wonderful collection of hepatitis fact sheets from testing to medications.
2019
Hep C Coalition 2019
Hep C Coalition: Fact Sheets for Compreensive HCV Services for People Who Use Drugs
This fact sheet helps advocates to demand from their governments a comprehensive hepatitis C package of services for people who use and inject drugs. Noting the political realities that certain provisions may not be available in some countries, we strive to see all these services, based on decades of public health evidence, implemented together.
2019
European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol (2018)
EASL Recommendations on Treatment of Hepatitis C 2018
The European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in 2018 and onwards.
2019
European Centre for Disease Prevention and Control, 2017
ECDC Technical Report Hepatitis B and C testing activities, needs, and priorities in the EU/EEA
The purpose of this work was to provide a baseline situation assessment to inform the guidance development process, and to assess the availability and feasibility of collecting additional morbidity and mortality data from EU/EEA Member States.
2019
ECDC 2019
Public Health Guidance on HIV, HBV and HCV Testing in the EU/EEA
To support Member States in their efforts to improve case detection and uptake of testing programmes as part of the global effort to eliminate viral hepatitis and HIV as public health threats by 2030, ECDC is providing this evidence-based guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV.
2019
Liverpool University
University of Liverpool HCV Medication Interaction Website
Website database to check HCV medication interactions with other drugs
2019
Correlation
Monitoring of HCV testing in low threshold drug services - Heike Zurhold
This report documents monitoring aimed at collecting data on the proportion of drug users who have been tested for HCV, the prevalence of HCV and the number of drug users that should be tested for hepatitis C.
2019
Correlation
Drug Consumption Rooms: Evidence and Practice
2019
Correlation
Data Collection Protocal for Specialist Harm Reduction Agencies
2019
Correlation
Evaluation Guide
2019
WHO Regional Office for Europe
Action plan for the health sector response to viral hepatitis in the WHO European Region
This first Action plan for viral hepatitis in the WHO European Region adapts the Global health sector strategy on viral hepatitis, 2016–2021 to the context of the European Region. The plan was developed through a participatory process, finalized and endorsed at the 66th session of the WHO Regional Committee for Europe, along its resolution EUR/RC66/R10.
2019
Am J Public Health.
Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. Zibbell et al.
These findings strongly suggest that the national increase in acute HCV infection is related to the country's opioid epidemic and associated increases in IDU.
2019
Journal of Hepatology 2017
Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond. M. Hellard et al.
The implication of this work is that for many countries the elimination of hepatitis C as a public health threat is not going to happen by chance. A number of barriers need to be overcome, requiring a focused effort from governments and health services. The first barrier is that widespread treatment scale-up is currently precluded by restricted and inconsistent access policies in many European countries.3,4
2019
2017 European Association for the Study of the Liver.
Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients, Maria P. Carrieri, et al.
Coffee has anti-inflammatory and hepatoprotective properties but its effect on mortality risk has never been investigated in patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). This study shows that elevated coffee consumption (≥3 cups/day) halves all-cause mortality risk in patients co-infected with HIV-HCV. The benefits of coffee extracts and supplementing dietary intake with other anti-inflammatory compounds need to be evaluated in this population.
2020
ECDC
Monitoring the responses tohepatitis B and C epidemicsin the EU/EEA Member States2019
ECDC TECHNICAL REPORT
2020
BMC Infectious Diseases
Beyond clinical outcomes: the social andhealthcare system implications of hepatitisC treatment
Hepatitis C virus (HCV) infections in people who inject drugs (PWID) can now be treated and cured.However, the impact that HCV treatment has on drug-user health, practices and wellbeing is not known. The aim ofthis research was to understand the non-clinical impact that HCV treatment has in PWID and their reasons foraccessing and completing treatment.
2019
WHO Regional Office for Europe
Action plan for the health sector response to viral hepatitis in the WHO European Region
This very first Action plan for the health sector response to viral hepatitis in the WHO European Region has been developed through a truly inclusive consultative approach. It draws on the expertise of an advisory committee and has benefited from the input of Member States, major partners and civil society, including patient organizations which represent the people who live with viral hepatitis in Europe.
2020
EASL
EASL Policy Statement:Drug use and the global hepatitis C elimination goal
2016
Improving testing rates for blood-borne viruses in prisons and other secure settings
Since 2014, Public Health England (PHE) Health and Justice has been supporting HM Prison & Probation Service (previously the National Offender Management Service) and National Health Services (NHS) England in the delivery of opt-out testing for blood-borne viruses (BBV) in all adult prisons in England. The evaluations include specific reports of offer and uptake of HIV, hepatitis B and hepatitis C testing within 72 hours of reception to prison as well as referral for treatment for those found infected. These data show that in England in 2016/17, 16 321 tests were conducted for hepatitis B infection, 21 268 for hepatitis C infection and 37 474 for HIV infection. The proportion of new receptions receiving tests for HCV increased from 5.3% in 2010/2011 to 11.5% in 2015/2016.